Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Current and Emerging Tobacco and Nicotine Products

The University of Texas MD Anderson Cancer Center

J. Robinson, PhD

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Weightloss in Menopause

Susan Brian

Tirzepatide Updates

Diana Isaacs

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs

Peripheral Arterial Disease: How To Prevent? When To Diagnose? How T…

Piedmont Heart Institute

A. Klein

GLP-1 Hysteria

Scripps Health

S. Harris

New Research: Side Effect of GLP1

Susan Brian

Understanding Variations in Risk of Lung Cancer Among Smokers

Masonic Cancer Center, University of Minnesota

J. Yuan